The approval marks the first new pharmacologic treatment in motion sickness in over four decades. The US Food and Drug ...
Emmaus Life Sciences has entered into a licensing and exclusive distribution agreement with NeoImmuneTech (NIT) for Endari, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback